Molecular Templates Past Earnings Performance
Past criteria checks 0/6
Molecular Templates has been growing earnings at an average annual rate of 15.8%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 17.2% per year.
Key information
15.8%
Earnings growth rate
24.0%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 17.2% |
| Return on equity | -219.7% |
| Net Margin | -61.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 30% Share Price Rise
Oct 10
Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00
Aug 17Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry
Jul 30Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding
Apr 03Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop
Dec 20There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise
Apr 17What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates
Nov 16Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook
Aug 14Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M
Aug 11Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt
Apr 29Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?
Dec 30Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates
Nov 25Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?
Sep 22News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts
Aug 15Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates
May 18Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts
Mar 21Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021
Feb 21Revenue & Expenses Breakdown
How Molecular Templates makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 25 | -16 | 15 | 0 |
| 31 Mar 24 | 32 | -18 | 17 | 0 |
| 31 Dec 23 | 57 | -8 | 19 | 0 |
| 30 Sep 23 | 53 | -26 | 21 | 0 |
| 30 Jun 23 | 50 | -47 | 23 | 0 |
| 31 Mar 23 | 48 | -60 | 24 | 0 |
| 31 Dec 22 | 20 | -93 | 26 | 0 |
| 30 Sep 22 | 35 | -81 | 27 | 0 |
| 30 Jun 22 | 33 | -87 | 31 | 0 |
| 31 Mar 22 | 44 | -78 | 33 | 0 |
| 31 Dec 21 | 39 | -83 | 34 | 0 |
| 30 Sep 21 | 24 | -101 | 33 | 0 |
| 30 Jun 21 | 26 | -94 | 32 | 0 |
| 31 Mar 21 | 18 | -110 | 29 | 0 |
| 31 Dec 20 | 19 | -105 | 27 | 0 |
| 30 Sep 20 | 22 | -92 | 26 | 0 |
| 30 Jun 20 | 21 | -107 | 23 | 0 |
| 31 Mar 20 | 19 | -85 | 21 | 0 |
| 31 Dec 19 | 22 | -69 | 20 | 0 |
| 30 Sep 19 | 21 | -60 | 18 | 0 |
| 30 Jun 19 | 24 | -27 | 17 | 0 |
| 31 Mar 19 | 20 | -28 | 16 | 0 |
| 31 Dec 18 | 13 | -30 | 14 | 0 |
| 30 Sep 18 | 9 | -31 | 14 | 0 |
| 30 Jun 18 | 3 | -36 | 12 | 0 |
| 31 Mar 18 | 2 | -31 | 11 | 0 |
| 31 Dec 17 | 3 | -24 | 10 | 0 |
| 30 Sep 17 | 3 | -20 | 8 | 0 |
| 30 Jun 17 | 2 | -13 | 6 | 0 |
| 31 Mar 17 | 3 | -11 | 5 | 0 |
| 31 Dec 16 | 2 | -13 | 4 | 0 |
| 31 Dec 15 | 1 | -7 | 3 | 0 |
Quality Earnings: MTEM is currently unprofitable.
Growing Profit Margin: MTEM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MTEM is unprofitable, but has reduced losses over the past 5 years at a rate of 15.8% per year.
Accelerating Growth: Unable to compare MTEM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTEM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: MTEM has a negative Return on Equity (-219.74%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 12:54 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Molecular Templates, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Carter Gould | Barclays |
| Tazeen Ahmad | BofA Global Research |
| Roger Song | Jefferies LLC |